Helicobacter pylori (H. pylori)

November 16, 2023

Nasty microbe H. pylori has Achilles’ heel

Vanderbilt researchers found that an H. pylori enzyme is essential for colonization of the stomach, suggesting it as a promising therapeutic target for H. pylori infection.

By Paul Govern
August 1, 2022

H. pylori and lung cancer

Specific biomarkers for H. pylori — a bacterium that infects the stomach — were associated with increased risk of lung cancer, Vanderbilt researchers have discovered.

By Leigh MacMillan
January 17, 2022

H. pylori, lipid loss and stomach cancer

H. pylori infection — a strong risk factor for stomach cancer — changes the composition of stomach lipids, which could offer new biomarkers for detecting premalignant changes, Vanderbilt researchers discovered.

By Leigh MacMillan
August 4, 2021

Study finds genetic factor undermines H. pylori treatment

Helicobacter pylori, a stomach-dwelling bacterium, is a strong risk factor for gastric cancer, peptic ulcers and other debilitating gastrointestinal disorders. Yet efforts to eradicate it using a combination of antibiotics and proton pump inhibitors (PPIs), which suppress gastric acid production, often fail.

By Bill Snyder
x-ray of stomach
October 15, 2020

Factor involved in stomach injury response identified

Researchers at Vanderbilt University Medical Center have identified a key factor that coordinates the body’s repair response to severe injury in the stomach caused, most commonly, by infection by the bacterium Helicobacter pylori.

By Bill Snyder
July 23, 2020

Stomach bug hit-and-run

The H. pylori machinery that “injects” an oncoprotein into stomach cells contributes to the development of gastric cancer, Vanderbilt researchers demonstrate.

By Leigh MacMillan
February 6, 2020

Powering H. pylori pathogenesis

Timothy Cover and colleagues report new insights into the sources of energy used by a bacterial “machine” linked to the pathogenesis of stomach cancer.
By Leigh MacMillan
October 3, 2019

A step toward gastric cancer

New research findings provide insight into the detrimental events that develop in response to H. pylori infection.
By Sanjay Mishra
April 25, 2019

Receptor’s role in stopping H. pylori

The immune receptor NOD1 may be a prime target for preventing or treating H. pylori infections — the most significant risk factor for stomach cancer, Vanderbilt researchers have discovered.
By Niyati Vachharajani
March 28, 2019

Cancer prevention drug also disables H. pylori bacterium

A medicine currently being tested as a chemoprevention agent for multiple types of cancer has more than one trick in its bag when it comes to preventing stomach cancer, Vanderbilt researchers have discovered.
By Leigh MacMillan
February 14, 2019

Probing H. pylori cancer protein

Understanding how a bacterial protein that influences the risk of stomach cancer is produced could guide new strategies for treatment.
By Leigh MacMillan
April 23, 2018

Toxin floats on lipid rafts

The bacterium H. pylori is a leading cause of stomach cancer, and Vanderbilt researchers are studying how one of its toxins gets into cells.
By Leigh MacMillan
February 2, 2017

New target for chronic infection

An enzyme in macrophage immune cells may be a good target for treating chronic infections, Vanderbilt researchers have discovered.
By VUMC News and Communications